What is Dihexa?
Dihexa is a small angiotensin IV–derived peptidomimetic (a two-amino-acid core with chemical caps) developed at Washington State University and sold online as a cognitive enhancer. The evidence is from rodent and cell studies. Its main mechanism paper was retracted in 2025, the original paper carries a 2021 expression of concern, and no human study has been published.
Video overview · 3:08
Dihexa: "10 Million Times Stronger Than BDNF"? What the Research Actually Shows
Where the "10 million times stronger than BDNF" claim came from, the rat studies, the 2025 retraction of its main mechanism paper, why it has never been tested in people, and its FDA, compounding and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
Dihexa is sold online as a brain booster, famously described as ten million times more powerful than BDNF, a protein that helps brain cells grow. The FDA's compounding panel is due to review it by early 2027. But the evidence is thin, and part of it has been retracted. Here's what's actually known.
Dihexa was developed at Washington State University from angiotensin four, a fragment of a blood-pressure hormone, and reworked to last longer and reach the brain. It's tiny: just two amino acids with chemical caps on each end, so it's a peptide look-alike more than a true peptide.
The idea was that dihexa boosts HGF and its receptor, c-Met, a growth signal that helps brain cells build new connections. But the main paper making that case was retracted in 2025. And the same growth pathway is active in many cancers, a theoretical risk that has never been tested.
Where does ten million times come from? A 2012 university press release about lab tests on nerve cells. The published paper didn't directly compare dihexa with BDNF. In that 2013 paper, rats given a memory-blocking drug did better in a water maze with dihexa, and results in old rats were more variable.
Since then, the record has gotten shakier. In 2021, the journal flagged the original paper with an expression of concern over possible image manipulation, and in 2025 it retracted the mechanism paper. Outside that lab, one mouse study of Alzheimer's-like disease reported benefits, while a 2024 rat study of Huntington's-like damage found none.
In people, there's nothing: no published human study, and no registered trial. A related company drug, fosgonimeton, is a different molecule from the same line of research. In Alzheimer's trials, it missed its main goals, and its Alzheimer's development was discontinued.
Dihexa is not FDA approved. The FDA says it has no human exposure data and lacks important safety information, and there are no long-term safety studies in animals either. It's on the agenda for the FDA's next compounding advisory meeting. In sport, it's likely covered by the ban on unapproved substances.
Does dihexa improve memory in people? Unproven: it has never been tested in people. Is it ten million times stronger than BDNF? Not supported: that came from a press release, not a head-to-head study. Does it work through HGF? Limited: the main paper was retracted. And is it a safe nootropic? Unknown: there's no human or long-term safety data.
The bottom line: dihexa helped memory-impaired rats, but its famous BDNF claim came from a press release, its main mechanism paper has been retracted, and it has never been tested in people. It isn't approved. For every study and source, see the dihexa profile on PepsRadar dot com.
Biological role or research focus
Cognition and neuronal signaling models.
A mouse task is not a demonstrated improvement in human memory, independence, or dementia progression.
Role reference: Retraction notice for the 2014 dihexa HGF/c-Met paper · J Pharmacol Exp Ther 2025 ↗
Names you may encounter
Angiotensin IV-derived peptidomimetic
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Experimental angiotensin-IV-derived peptidomimetic
- Research focus
- Cognition and neuronal signaling models
- Featured evidence
- Animal study
- Source check
- October 4, 2026
Quick answers
- Is Dihexa FDA approved?
- No. No FDA-approved drug contains Dihexa. Source ↗
- Is Dihexa safe?
- Dihexa is an experimental peptide-like compound with no human exposure data. FDA says it cannot tell whether dihexa would cause harm in people. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Dihexa banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
- Has the FDA taken action over Dihexa?
- Yes. Our records list 1 FDA action naming it, most recently on April 15, 2026: FDA listed Dihexa acetate among five bulk substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027 (date not yet set). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Dihexa in APP/PS1 mice (2021) | Animal study | APP/PS1 mice in an experimental neurodegeneration model. |
| Dihexa · zebrafish hair-cell protection (2015) | Animal laboratory study | Larval zebrafish lateral-line sensory hair cells exposed to aminoglycoside antibiotics. |
| Original dihexa paper · memory-impaired rats (2013) | Animal and laboratory study | Rats given scopolamine to impair memory, aged rats, and cultured rat brain cells. |
| Dihexa · Huntington's-like rat model (2024) | Animal study | Rats given 3-nitropropionic acid to produce Huntington's-like damage. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Animal study · 2021
Dihexa in APP/PS1 mice
What did this publication test, and what did it find?
- Population / model
- APP/PS1 mice in an experimental neurodegeneration model.
- Study design
- Animal intervention using water-maze behavior and neuronal, inflammatory, and signaling readouts.
- Main finding
- The report described improved maze performance and changes in neuronal and inflammation-related measures.
- Limits & context
- A mouse task is not a demonstrated improvement in human memory, independence, or dementia progression.
Animal laboratory study · 2015
Dihexa · zebrafish hair-cell protection
Was Dihexa examined outside cognition models?
- Population / model
- Larval zebrafish lateral-line sensory hair cells exposed to aminoglycoside antibiotics.
- Study design
- Drug-toxicity experiments testing Dihexa protection and inhibition of HGF-related signaling.
- Main finding
- Dihexa reduced hair-cell damage in the tested model. HGF antagonism and inhibition of downstream pathways reduced the protective response.
- How to read it
- This supports a model-specific mechanism hypothesis, not a treatment for human hearing loss.
- Limits & context
- Zebrafish hair cells and acute chemical injury differ from clinical hearing disorders. The study does not establish human cognitive benefit, therapeutic dosing, or long-term safety.
Source: Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. ↗
Animal and laboratory study · 2013
Original dihexa paper · memory-impaired rats
Did dihexa improve memory in impaired rats?
- Population / model
- Rats given scopolamine to impair memory, aged rats, and cultured rat brain cells.
- Study design
- Water-maze testing and counts of connections between cultured neurons.
- Main finding
- Treated scopolamine-impaired rats performed better in the water maze; results in aged rats were more variable. Cultured neurons formed more dendritic spines.
- How to read it
- The journal issued an expression of concern about this paper in 2021.
- Limits & context
- Rodent memory tasks do not establish benefit in human memory. The expression of concern and the 2025 retraction of the follow-up mechanism paper weaken confidence in this line of work.
Source: Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. ↗
Animal study · 2024
Dihexa · Huntington's-like rat model
Did dihexa protect against brain damage in an independent rat model?
- Population / model
- Rats given 3-nitropropionic acid to produce Huntington's-like damage.
- Study design
- Motor and memory testing with and without the dihexa compound (PNB-0408).
- Main finding
- The compound did not protect against the motor or memory deficits.
- Limits & context
- One model and one laboratory. It is a negative animal result, not a human study.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming Dihexa as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 3 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. ↗
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 Jan 1 · Journal Article, Review
Read available full text ↗
The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. ↗
The Journal of pharmacology and experimental therapeutics · 2014 Nov · Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Retracted Publication
Read available full text ↗
The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease. ↗
Journal of Alzheimer's disease : JAD · 2015 · Journal Article, Research Support, Non-U.S. Gov't, Review
Risks & interactions
Dihexa is an experimental peptide-like compound with no human exposure data. FDA says it cannot tell whether dihexa would cause harm in people.
FDA found no human exposure data for any route. Evidence comes from mouse, rat and zebrafish studies, and the effects of long-term activation of growth-factor (HGF/c-Met) signaling in people are unknown.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · Dihexa in APP/PS1 mice (2021) ↗ · Angiotensin IV-derived peptides and the HGF/c-Met system (2014) ↗
Safety & what remains unknown
This study cannot define long-term human safety, interactions, or the consequences of changing growth-related signaling.
Evidence boundaries
A mouse task is not a demonstrated improvement in human memory, independence, or dementia progression.
What FDA flagged
FDA says it has no human exposure data for dihexa and lacks important safety information. No long-term safety studies in animals or people were found.
Source: FDA · Bulk substances that may present significant safety risks ↗
FDA compounding review
FDA has listed dihexa acetate among five substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027. No date had been set when this was checked. A committee vote is advice to FDA, and inclusion on the bulks list would not make it an approved drug.
Source: FDA · Pharmacy Compounding Advisory Committee meeting before the end of February 2027 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "Dihexa acetate". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. It may alternatively fall under S2.3 (growth factor modulators) because it is described as acting on the hepatocyte growth factor system. source
FDA actions
- FDA listed Dihexa acetate among five bulk substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027 (date not yet set). Any committee vote is advisory. (2026-04-15) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
The popular claim that dihexa is "ten million times" more potent than BDNF comes from a 2012 university press release about lab tests on nerve cells; the published paper did not compare the two directly. No published or registered human trial of dihexa exists. Fosgonimeton, a different molecule from the same research line, missed its main goals in Alzheimer's trials.
Source: Washington State University press release · ScienceDaily 2012 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
Dihexa was designed from angiotensin IV, a fragment of a blood-pressure hormone, to resist breakdown and reach the brain. Its developers proposed that it boosts hepatocyte growth factor (HGF) and its receptor, c-Met, helping brain cells form new connections.
The 2014 paper that made the HGF/c-Met case was retracted in 2025, and the 2013 paper that first described dihexa received an expression of concern in 2021 citing possible image manipulation. HGF/c-Met is also a signaling pathway active in many cancers, so stimulating it carries a theoretical risk that has not been studied.
Source: Retraction notice for the 2014 dihexa HGF/c-Met paper · J Pharmacol Exp Ther 2025 ↗
Questions worth asking
- Does better mouse maze performance prove a dementia treatment?
- What material, population, and route were actually studied?
- A mouse task is not a demonstrated improvement in human memory, independence, or dementia progression.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Does better mouse maze performance prove a dementia treatment?
No. Clinical benefit requires trials measuring outcomes in people with the relevant condition.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Is dihexa really ten million times stronger than BDNF?
That figure comes from a 2012 press release about lab tests on nerve cells. The published paper did not directly compare dihexa with BDNF, and neither has been compared in people.
Source: Washington State University press release · ScienceDaily 2012 ↗
Has dihexa been tested in people?
No published human study or registered trial was found. The FDA says it has no human exposure data.
Source: FDA · Bulk substances that may present significant safety risks ↗
References & editorial record
- PubMed · PMID 34827486 ↗
- Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. ↗
- Retraction notice for the 2014 dihexa HGF/c-Met paper · J Pharmacol Exp Ther 2025 ↗
- Expression of concern for the 2013 dihexa paper · J Pharmacol Exp Ther 2021 ↗
- Alzheimer's Drug Discovery Foundation · Cognitive Vitality report on dihexa ↗
- Washington State University press release · ScienceDaily 2012 ↗
- Fosgonimeton · Alzforum ↗
- Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. ↗
- Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats. ↗
- FDA · Bulk substances that may present significant safety risks ↗
- FDA · Pharmacy Compounding Advisory Committee meeting before the end of February 2027 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
